These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

678 related items for PubMed ID: 25496917

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects.
    Zimmerman Y, Foidart JM, Pintiaux A, Minon JM, Fauser BC, Cobey K, Coelingh Bennink HJ.
    Contraception; 2015 Feb; 91(2):127-33. PubMed ID: 25604900
    [Abstract] [Full Text] [Related]

  • 3. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
    Coelingh Bennink HJT, Zimmerman Y, Laan E, Termeer HMM, Appels N, Albert A, Fauser BCJM, Thijssen JHH, van Lunsen RHW.
    Contraception; 2017 Nov; 96(5):322-329. PubMed ID: 27393080
    [Abstract] [Full Text] [Related]

  • 4. Maintaining physiologic testosterone levels during combined oral contraceptives by adding dehydroepiandrosterone: II. Effects on sexual function. A phase II randomized, double-blind, placebo-controlled study.
    van Lunsen RHW, Zimmerman Y, Coelingh Bennink HJT, Termeer HMM, Appels N, Fauser BCJM, Laan E.
    Contraception; 2018 Jul; 98(1):56-62. PubMed ID: 29490289
    [Abstract] [Full Text] [Related]

  • 5. The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive.
    Zimmerman Y, Coelingh Bennink HJ, Wouters W, Ebes F, Fauser BC.
    Eur J Contracept Reprod Health Care; 2013 Dec; 18(6):489-500. PubMed ID: 23944295
    [Abstract] [Full Text] [Related]

  • 6. The bioequivalence of the contraceptive steroids ethinylestradiol and drospirenone is not affected by co-administration of dehydroepiandrosterone.
    Zimmerman Y, Wouters W, Coelingh Bennink HJ.
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):206-14. PubMed ID: 23550808
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J.
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [Abstract] [Full Text] [Related]

  • 8. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S, Davies E, Fearns S, McKinnon C, Carter R, Gerlinger C, Smithers A.
    Clin Drug Investig; 2010 Apr; 30(5):325-36. PubMed ID: 20384388
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the quality of life and sexual functioning of women using a 30-microg ethinyloestradiol and 3-mg drospirenone combined oral contraceptive.
    Skrzypulec V, Drosdzol A.
    Eur J Contracept Reprod Health Care; 2008 Mar; 13(1):49-57. PubMed ID: 18283600
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
    Maloney JM, Dietze P, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P.
    J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
    Guang-Sheng F, Mei-Lu B, Li-Nan C, Xiao-Ming C, Zi-Rong H, Zi-Yan H, Xiao-Ping J, Jian L, Shu-Ying W, Cheng-Liang X, Zheng-Ai X, Tian-Fu Y.
    Clin Drug Investig; 2010 Sep; 30(6):387-96. PubMed ID: 20201608
    [Abstract] [Full Text] [Related]

  • 12. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea.
    Witjes H, Creinin MD, Sundström-Poromaa I, Martin Nguyen A, Korver T.
    Eur J Contracept Reprod Health Care; 2015 Sep; 20(4):296-307. PubMed ID: 25712537
    [Abstract] [Full Text] [Related]

  • 13. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
    Lucky AW, Koltun W, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J.
    Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
    [Abstract] [Full Text] [Related]

  • 14. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R.
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [Abstract] [Full Text] [Related]

  • 15. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R.
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [Abstract] [Full Text] [Related]

  • 16. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM, Kaptein AA, Helmerhorst FM.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD006586. PubMed ID: 22336820
    [Abstract] [Full Text] [Related]

  • 17. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
    Palli MB, Reyes-Habito CM, Lima XT, Kimball AB.
    J Drugs Dermatol; 2013 Jun 01; 12(6):633-7. PubMed ID: 23839178
    [Abstract] [Full Text] [Related]

  • 18. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
    Palatsi R, Reinilä M, Kivinén S.
    Acta Derm Venereol; 1986 Jun 01; 66(3):225-30. PubMed ID: 2426899
    [Abstract] [Full Text] [Related]

  • 19. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
    Thorneycroft lH, Gollnick H, Schellschmidt I.
    Cutis; 2004 Aug 01; 74(2):123-30. PubMed ID: 15379365
    [Abstract] [Full Text] [Related]

  • 20. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction.
    Davis SR, Bitzer J, Giraldi A, Palacios S, Parke S, Serrani M, Mellinger U, Nappi RE.
    J Sex Med; 2013 Dec 01; 10(12):3069-79. PubMed ID: 24034466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.